Follow the 株式会社リボミック share price and the full management transaction log of the company, a listed equity based in Japan. Shares are quoted on JP JP, under the authority of EDINET (Japan FSA). Market capitalisation: €3.7bn. The latest transaction was filed on 24 April 2026 (Holding update). Among the most active insiders: Evo Fund. All data is accessible without an account.
23
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
18Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Ribomic Inc. is a Japanese company listed on the XTKS market, specializing in the development of drugs based on ribozyme technology. It focuses on innovative treatments for various diseases.